196 related articles for article (PubMed ID: 28371223)
1. Faster insulin action is associated with improved glycaemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes.
Ruan Y; Thabit H; Leelarathna L; Hartnell S; Wilinska ME; Tauschmann M; Dellweg S; Benesch C; Mader JK; Holzer M; Kojzar H; Evans ML; Pieber TR; Arnolds S; Hovorka R;
Diabetes Obes Metab; 2017 Oct; 19(10):1485-1489. PubMed ID: 28371223
[TBL] [Abstract][Full Text] [Related]
2. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.
Thabit H; Elleri D; Leelarathna L; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Barnard KD; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
Diabetes Obes Metab; 2015 May; 17(5):452-8. PubMed ID: 25492378
[TBL] [Abstract][Full Text] [Related]
3. Experiences of closed-loop insulin delivery among pregnant women with Type 1 diabetes.
Farrington C; Stewart ZA; Barnard K; Hovorka R; Murphy HR
Diabet Med; 2017 Oct; 34(10):1461-1469. PubMed ID: 28631849
[TBL] [Abstract][Full Text] [Related]
4. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
[TBL] [Abstract][Full Text] [Related]
5. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes.
Ruan Y; Bally L; Thabit H; Leelarathna L; Hartnell S; Tauschmann M; Wilinska ME; Evans ML; Mader JK; Kojzar H; Dellweg S; Benesch C; Arnolds S; Pieber TR; Hovorka R
Diabetes Obes Metab; 2018 Aug; 20(8):2004-2008. PubMed ID: 29577536
[TBL] [Abstract][Full Text] [Related]
7. Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.
Emami A; Willinska ME; Thabit H; Leelarathna L; Hartnell S; Dellweg S; Benesch C; Mader JK; Holzer M; Kojzar H; Pieber TR; Arnolds S; Evans ML; Hovorka R
Diabetes Technol Ther; 2017 Jul; 19(7):433-437. PubMed ID: 28463010
[TBL] [Abstract][Full Text] [Related]
8. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.
McAuley SA; Trawley S; Vogrin S; Ward GM; Fourlanos S; Grills CA; Lee MH; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; Colman PG; MacIsaac RJ
Diabetes Care; 2022 Feb; 45(2):381-390. PubMed ID: 34844995
[TBL] [Abstract][Full Text] [Related]
9. Effect of frequency of sensor use on glycaemic control in individuals on sensor-augmented pump therapy with and without Predictive Low Glucose Management System.
Abraham MB; Smith GJ; Nicholas JA; Fairchild JM; King BR; Ambler GR; Cameron FJ; Davis EA; Jones TW;
Diabetes Res Clin Pract; 2020 Jan; 159():107989. PubMed ID: 31866529
[TBL] [Abstract][Full Text] [Related]
10. Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol.
Musolino G; Allen JM; Hartnell S; Wilinska ME; Tauschmann M; Boughton C; Campbell F; Denvir L; Trevelyan N; Wadwa P; DiMeglio L; Buckingham BA; Weinzimer S; Acerini CL; Hood K; Fox S; Kollman C; Sibayan J; Borgman S; Cheng P; Hovorka R
BMJ Open; 2019 Jun; 9(6):e027856. PubMed ID: 31164368
[TBL] [Abstract][Full Text] [Related]
11. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes.
Stewart ZA; Wilinska ME; Hartnell S; Temple RC; Rayman G; Stanley KP; Simmons D; Law GR; Scott EM; Hovorka R; Murphy HR
N Engl J Med; 2016 Aug; 375(7):644-54. PubMed ID: 27532830
[TBL] [Abstract][Full Text] [Related]
12. Closed loop insulin delivery in diabetes.
Battelino T; Omladič JŠ; Phillip M
Best Pract Res Clin Endocrinol Metab; 2015 Jun; 29(3):315-25. PubMed ID: 26051293
[TBL] [Abstract][Full Text] [Related]
13. Is an artificial pancreas (closed-loop system) for Type 1 diabetes effective?
Boughton CK; Hovorka R
Diabet Med; 2019 Mar; 36(3):279-286. PubMed ID: 30183096
[TBL] [Abstract][Full Text] [Related]
14. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis.
Nimri R; Muller I; Atlas E; Miller S; Kordonouri O; Bratina N; Tsioli C; Stefanija MA; Danne T; Battelino T; Phillip M
Pediatr Diabetes; 2014 Mar; 15(2):91-9. PubMed ID: 23944875
[TBL] [Abstract][Full Text] [Related]
15. Randomized Controlled Trial of Mobile Closed-Loop Control.
Kovatchev B; Anderson SM; Raghinaru D; Kudva YC; Laffel LM; Levy C; Pinsker JE; Wadwa RP; Buckingham B; Doyle FJ; Brown SA; Church MM; Dadlani V; Dassau E; Ekhlaspour L; Forlenza GP; Isganaitis E; Lam DW; Lum J; Beck RW;
Diabetes Care; 2020 Mar; 43(3):607-615. PubMed ID: 31937608
[TBL] [Abstract][Full Text] [Related]
16. Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp.
Ly TT; Roy A; Grosman B; Shin J; Campbell A; Monirabbasi S; Liang B; von Eyben R; Shanmugham S; Clinton P; Buckingham BA
Diabetes Care; 2015 Jul; 38(7):1205-11. PubMed ID: 26049550
[TBL] [Abstract][Full Text] [Related]
17. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
[TBL] [Abstract][Full Text] [Related]
18. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol.
Leelarathna L; Dellweg S; Mader JK; Barnard K; Benesch C; Ellmerer M; Heinemann L; Kojzar H; Thabit H; Wilinska ME; Wysocki T; Pieber TR; Arnolds S; Evans ML; Hovorka R;
BMJ Open; 2014 Sep; 4(9):e006075. PubMed ID: 25186158
[TBL] [Abstract][Full Text] [Related]
19. Comparison Between Closed-Loop Insulin Delivery System (the Artificial Pancreas) and Sensor-Augmented Pump Therapy: A Randomized-Controlled Crossover Trial.
Haidar A; Legault L; Raffray M; Gouchie-Provencher N; Jacobs PG; El-Fathi A; Rutkowski J; Messier V; Rabasa-Lhoret R
Diabetes Technol Ther; 2021 Mar; 23(3):168-174. PubMed ID: 33050728
[No Abstract] [Full Text] [Related]
20. The Incremental Benefits of the Predictive Low-Glucose Suspend Function Compared to the Low-Glucose Suspend Function as Automation Against Hypoglycemia in Sensor-Augmented Pump Therapy.
Beato-Víbora PI; Gil-Poch E; Galán-Bueno L; Lázaro-Martín L; Arroyo-Díez FJ
J Diabetes Sci Technol; 2018 Nov; 12(6):1241-1243. PubMed ID: 30058373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
